France

On August 2, 2024, the French National Authority for Health (HAS) published a report presenting the program for evaluating targeted high-throughput sequencing procedures. The program defined indications for which the technology will be evaluated with a view to its transitioning to regular reimbursement under the Statutory Health

On August 2, 2024, the HAS published positive opinions on the inclusion of targeted high-throughput sequencing of gene panels in the medical management of lung cancer, gastrointestinal stromal tumors, and chronic lymphocytic leukemia in the NABM Nomenclature. This is a consequence of the efforts to disburden the innovation funding budget and clean the List of IVD tests outside the Nomenclature (Liste des actes hors nomenclatures, AHN, i.e., the merged 2023 RIHN List and the Supplementary List funded outside Statutory Health Insurance via the research and innovation budget).

At the end of July 2024, the French Ministry of Health released a document on the RIHN reform process, including the description on the new RIHN application and evaluation process, but also how the HAS will evaluate tests currently covered in the RIHN Nomenclature, with the purpose of of deciding whether these tests will be granted permanent reimbursement, or will be excluded from coverage within the statutory health insurance. Cleaning the current AHN List will allow for the financing of truly innovative tests patients need.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in July 2024. Nine recommendations were published concerning the registration of medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern cardiovascular, neurovascular, interventional radiology, nephrology and urology, orthopedic, endocrine devices, and in-vitro diagnostic tests, as well as medical aids.

In the middle of July 2024, the new version of the classification of procedure codes (CCAM v.76) was published. Several changes were introduced, including creating 14 new codes in diagnostic imaging, men’s health, and neuromodulation technology groups.

The new framework agreement on the medical devices included in the LPPR was signed on July 2, 2024.

On July 16, 2024, the French Ministry of Labor, Health and Solidarity published the merged 2024 List of acts outside the nomenclature financed under MERRI G03.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in June 2024. Twelve recommendations were published concerning the registration of medical devices or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern cardiovascular and endocrine devices, as well as medical aids.

On June 18, 2024, France introduced the tariffs of €10-€15 for rapid diagnostic tests performed by pharmacists. This initiative enables pharmacists to swiftly diagnose and manage common conditions, such as Group A Streptococcal pharyngitis and urinary tract infections.

In the first half of June 2024, the French National Authority for Health (HAS) published its positive opinions regarding the reimbursement of several services in France.

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in May 2024. Seven recommendations were published concerning the registration of medical devices or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). Opinions concern neurovascular, neuromodulation, endocrine, ophthalmology, and orthopedic devices, as well as medical aids.

On May 17, 2024, the French National Authority for Health (HAS) announced the start of the application period for evaluating procedures and IVD tests to be included in the 2025 HAS working program.